These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23684755)

  • 1. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
    Di Iorio B; Molony D; Bell C; Cucciniello E; Bellizzi V; Russo D; Bellasi A;
    Am J Kidney Dis; 2013 Oct; 62(4):771-8. PubMed ID: 23684755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J; Asmus HG; Holzer H; Brunkhorst R; Krause R; Schulz W; Neumayer HH; Raggi P; Bommer J
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
    Qunibi W; Moustafa M; Muenz LR; He DY; Kessler PD; Diaz-Buxo JA; Budoff M;
    Am J Kidney Dis; 2008 Jun; 51(6):952-65. PubMed ID: 18423809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
    Block GA; Raggi P; Bellasi A; Kooienga L; Spiegel DM
    Kidney Int; 2007 Mar; 71(5):438-41. PubMed ID: 17200680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
    Russo D; Miranda I; Ruocco C; Battaglia Y; Buonanno E; Manzi S; Russo L; Scafarto A; Andreucci VE
    Kidney Int; 2007 Nov; 72(10):1255-61. PubMed ID: 17805238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
    Suki WN; Zabaneh R; Cangiano JL; Reed J; Fischer D; Garrett L; Ling BN; Chasan-Taber S; Dillon MA; Blair AT; Burke SK
    Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in end stage renal disease: calcium carbonate vs. sevelamer.
    Borzecki AM; Lee A; Wang SW; Brenner L; Kazis LE
    J Clin Pharm Ther; 2007 Dec; 32(6):617-24. PubMed ID: 18021340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.